Introduction: Valproic acid (VPA) is a widely prescribed antiepileptic drug, which might induce serious hepatic disorders . Silymarin is currently used as a supportive therapy of liver disorders. Aim of the study: In this study we evaluated the protective effects of silymarin on valproic acid induced hepatotoxicity . Material and Methods: seventy adult male albino rats were divided into 7 groups (10 each), (Ia) negative control, (Ib) positive control, (II) silymarin group, received 17.5 mg/kg. (IIIa) low dose VAP group, received 200mg/kg , (IIIb) high dose VAP group received 400 mg/kg (IVa) low dose VPA + silymarin group and (IVb) high dose VPA + silymarin group received doses as previously mentioned. The drugs were gavaged once daily, 6 days/week for 8 weeks, at the end of the experiment rats were sacrificed and estimation of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the blood, malondialdehyde (MDA) and glutathione peroxidase (GSH-Px) in liver tissues and histopathological and immunnohistochemical examination of liver tissues were carried out. Results: this study showed significant increase in serum ALT, ALP and hepatic MDA contents while GSH-Px activity significantly reduced (especially in high dose VPA group) when compared with the control. Histopathological changes showed patchy microvesicular steatosis, focal necrosis of hepatocytes, dilated congested central vein and sinusoids. Immunolocalization of Bcl-2 revealed dose dependent weak cytoplasmic staining in the hepatocytes surrounding the central vein. VPA+ Silymarin groups showed partial improvement. Conclusion: It concluded that VPA has dose dependent toxic effects on liver that might be ameliorated by concomitant use of silymarin.
Introduction
Valproic acid (2-propyl-pentanoic acid, VPA) is a broad-spectrum antiepileptic drug that is now used commonly for several other neurological and psychiatric indications, it considered to be a safe antiepileptic drug in a wide range of epileptic conditions in children and adults. It is usually well tolerated, but serious complications, including hepatotoxicity, hyperammonemic encephalopathy, fatal hemorrhagic pancreatitis, teratogenicity and bone marrow suppression may occur. VPA is extensively metabolized by the liver via glucuronic acid conjugation, mitochondrial β-and cytosolic ω-oxidation to produce multiple metabolites ( GarciaMorales et al., 2007; Lheureux Hantson, 2009 and Wang et al., 2012) .
The mechanism of VPA hepatotoxicity is still not understood, although multiple factors are likely to contribute to the toxicity, including development of oxidative stress (Chang and Abbott, 2006) , formation of reactive metabolites of VPA (Tang, 2007) and covalent binding to cellular proteins (Leone et al., 2007; Nakayama et al., 2009) .
Silymarin is a purified extract from the seeds of Silybum marinum L. (Asteraceae) also called "milk thistle". It was shown that silymarin consists of a large number of flavonoids. Currently, silymarin is widely used as a hepatoprotectant and as a supportive therapy for liver disorders such as cirrhosis, hepatitis and fatty acid infiltration due to alcohol and toxic chemicals (Ball and Kowdley, 2005; Kren and Walterova, 2005) .
Silymarin is capable of protecting liver cells directly by stabilizing the membrane permeability through inhibiting lipid peroxidation and preventing liver glutathione depletion (Skottova et al., 2003) .
Silymarin has proved success in protecting the liver cell from oxidative effect of carbon tetrachloride , paracetamol or D-galactosamine via the antioxidant properties of flavonoids, which includes the inhibition of the synthesis of phosphatidylcholine, stimulating of hepatic synthesis of RNA proteins, stimulate the RNA polymerase I , and further the ribosomal RNA and the protein synthesis ( Ramasamy and Agarwal , 2008) . So, this study aims at evaluating the protective effects of silymarin on VPA-induced hepatotoxicity. Resources, 1996) .
Material and methods

Drugs
Methods
Experimental design
Grouping of animals
The rats were divided into seven groups; each group consisted of 10 rats.
− Group Ia (Negative control): kept on normal diet and tape water without treatment till end of the experiment. − Group 1b (Positive control): Sham received 1 ml of 0.9% saline by gavage for 6 days/week for 8 weeks. − Group II (silymarin): Rats received 17.5 mg/kg of silymarin dissolved in 1 ml saline once daily by gavage for 6 days/week for 8 weeks (Kucharz and Kott , 1994) . N.B.: LD50 in rats 385mg/kg in rats (Dixit et al., 2007) . − Group IIIa (low dose valproic) :
Rats were given 200 mg/kg VPA dissolved in 0.9% saline once daily by gavage for 6 days/week for 8 weeks Kabakus et al., (2005) , Bairy et al., (2010) . The dose of VPA is based on that administration of an oral dose of VPA 200 mg/kg/day or greater represents 50% of the maximum human daily dose or greater (Walker et al., 1990 and Kabakus et al., 2005) . − Group IIIb (high dose valproic) :
Rats were given VPA 400 mg/kg dissolved in 0.9% saline once daily by gavage for 6 days/week for 8 weeks (Kabakus et al., (2005) and Bairy et al., (2010) ). − Group IVa (low dose valproic + silymarin): Rats were given 200 mg/kg of VPA (dissolved in 0.9% saline) and silymarin 17.5 mg/kg (dissolved in 1 ml saline) once daily by gavage for 6 days/week for 8 weeks. − Group IVb (high dose valproic + silymarin): Rats were given 400 mg/kg of VPA (dissolved in 0.9% saline) and silymarin 17.5 mg/kg (dissolved in 1 ml saline) once daily by gavage for 6 days/week for 8 weeks. At the end of the experiment rats were anaesthetized by ether and blood samples were collected from the retro-orbital plexus for estimation of liver functions (ALT and ALP), then rats were sacrificed by decapitation and abdominal incision was done and the liver extracted for measurement of hepatic MDA content and GSH-Px activity as follows:
Assessment of liver function tests (LFTs)
Alanine aminotransferase (ALT) (IU/L) Estimation of ALT has been carried out using kits of Eli Tech-diagnostic. It was done as described by Sokmen et al., (2012) quoted from Reitman and Frankel, (1957) according to the pamphlet of Eli techdiagnostic by method of enzymatic UV kinetic.
Alkaline phosphatase enzyme (ALP) (IU/L)
Its estimation has been carried out by twopoint method according to Walter and Schutt, (1974) .
Assessment of tissue oxidative stress markers
Each liver specimen was divided into 2 parts, one part was wrapped with aluminum foil and embedded in liquid nitrogen for 1 hour then kept frozen in -80°C till used to asses MDA level and GSH-px enzyme activity in tissues. Assessment of MDA (nmol/mg protein) level was done as described by Satoh, (1978) , while assessment of enzyme activity of GSH-px (nmol/gm tissue) was done according to Durak et al., (1996) , this is according to the pamphlet of Bio diagnostic kits using calorimetric method. The 2nd parts were preserved for histopathological examination.
Histologic study
Light microscope examination (HandE)
For light microscopic study, liver specimens were fixed in 10% formalin saline for histopathological examination using Hematoxylin and Eosin (HandE) stain by following the method described by Wilson and Gamble, (2002) .
Immunohistochemical study
Immunostaining was performed using the avidin-biotin peroxidase technique for localization of Bcl-2. Paraffin sections mounted on coated slides were deparaffinized and treated with 0.01 M citrate buffer for 10 minutes to unmask antigens. Then sections were incubated in H2O2 for 10 minutes to abolish endogenous peroxidase activity before blocking with 5% horse serum for 2 hs at room temperature to inhibit the nonspecific immunoreactions. Primary monoclonal anti-Bcl-2 serum (Cell Marque Lot., 27068) were applied at 1:5000 dilutions. Sections were incubated with primary monoclonal antisera for 36 h at 4Cº. After washing they were incubated with biotinylated secondary antibodies for 5 hrs and then followed by avidin-biotin peroxidase complex. Finally immune reaction was visualized with 0.05% diaminobenzidine. Then the slides were counter stained with Mayer's hematoxylin before mounting (Happerfield et al., 1993) .
Statistical analysis
Data were represented as means ± SD. The differences were compared for statistical significance by ANOVA and post hoc Tukey's tests. Difference was considered significant at p < 0.05. The statistical analysis was performed using Epi-Info version 6.1 (Dean et al., 2000) .
Results
I-Biochemical results
Statistical comparison between the negative control (Ia), positive control (Ib) and silymarin groups regarding LFTs (ALT and ALP) and hepatic oxidative stress markers (MDA and GSH-Px) revealed no significant difference (P > 0.05) by ANOVA test, so the negative control (Ia) was used for comparison with other groups of the study.
As regard groups IIIa, IIIb , IVa and IVb they showed significant difference (P<0.05) in LFTs (ALT and ALP) and hepatic oxidative stress markers (MDA and GSH-Px) in comparison with control group (Table 1and Figure 1 ).
Effects of valproic acid on the hepatic functions (ALTandALP) , MDA contents and antioxidant GSH--PX enzyme activity in liver tissues
Valproic acid caused significant increase in the mean values of ALT, ALP and hepatic MDA contents (P < 0.05) while GSH-Px activity significantly reduced (P < 0.05) in group IIIa and IIIb when compared with control group. These effects were dose dependent as there was a statistically significant increase in the mean values of ALT, ALP and hepatic MDA contents (P < 0.05) while GSH-Px activity significantly reduced (P < 0.05) in group IIIb (400 mg/kg) when compared with group IIIa (200 mg/kg) (Table 1and Figure 1 ).
Effects of silymarin on the hepatic functions (ALTandALP), MDA contents and antioxidant in liver tissues of rats received valproic acid
Silymarin treatment significantly (P < 0.05) improved the mean values of (ALT andALP) as well as oxidative stress markers (MDA and GSH-Px) in group IVa in comparison with group IIIa but still significantly increased(P < 0.05) in comparison with the control group, which means partial improvement. As regard IVb group, silymarin treatment significantly improved liver functions (ALT and ALP) and oxidative stress markers (MDA andGSH-Px) in comparison with group IIIb , but still significantly increased when compared with the control, which means partial improvement. As regarding VPA + silymarin treated groups, the improvement was significant (P<0.05) in group IVa in comparison with IVb for all parameters except ALT (Table 1and Figure 1 ).
II-Histopathologic results
Examination of the specimens taken from the control groups (Iaand Ib) and silymarin group showed the normal hexagonal lobules with central veins and peripheral hepatic triads (portal areas) contained branches of the portal vein, hepatic artery and bile duct. Hepatocytes are arranged in trabeculae running radiantly from the central vein. They have stippled appearance of the acidophilic cytoplasm with large vesicular nuclei. The trabeculae are separated by sinusoidal spaces (Figure 2 ). Immunohistochemical stained sections revealed dark brown positive reaction in the cytoplasm of hepatocytes surrounding the central vein (Figure 3) .
Examination of HandE stained liver sections of 200 mg/kg VPA group showed patchy microvesicular steatosis, dilated congested central vein and dilated congested sinusoids in some lobules. There are also cloudy swelling and hydropic degeneration in hepatocytes especially in zone 3 hepatocytes (hepatocytes surrounding central vein) (Figure 4) . Immunolocalization of Bcl-2 in all examined liver specimens of this group revealed weak cytoplasmic staining in the hepatocytes surrounding the central vein ( Figure 5 ).
Rats received 200 mg/kg VPA and silymarin 17.5 mg/kg showed marked improvement. Hepatic plates return to normal in most areas with decrease in hydropic degeneration. The specimens showed decrease in the congestion and dilation of the central vein and sinusoids. There was marked regression in microvesicular steatosis in most of liver sections ( Figure 6 ). Immunohistochemical stained sections revealed dark brown positive reaction in the cytoplasm of hepatocytes surrounding the central vein (Figure 7) .
Examination of HandE stained liver sections of 400 mg/kg VPA group showed patchy microvesicular steatosis and focal necrosis of hepatocytes (the hepatocytes replaced by neutrophils, especially around central vein), dilated congested central vein and sinusoids in most of the hepatic lobules (Figures 8,9 ). Immunohistochemical stained sections revealed weak Bcl-2 reaction in the cytoplasm of hepatocytes surrounding the central vein ( Figure  10) .
Examination of HandE stained liver sections of rats received 400 mg/kg VPA and silymarin 17.5mg/kg showed partial improvement. Hepatic plates return to normal in some areas with decrease in hydropic degeneration. The specimens showed decrease in the congestion and dilation of the central vein and sinusoids. There was regression in microvesicular steatosis in some of liver sections (Figure 11 ). Immunohistochemical stained sections revealed moderate brown positive reaction in the cytoplasm of hepatocytes surrounding the central vein ( Figure 12 ). 
Discussion
This study evaluated the potential protective effects of silymarin against VPA-induced liver damage in experimental animals. The results indicated that VPA induced dose dependent hepatotoxicity and associated with increased ALT and ALP. In accordance with these results, Schulpis et al., (2006) and Sokmen et al., (2012) found that VPA treated rats showed significant increase in the levels of hepatocellular (AST, ALT) and hepatobiliary (ALP ) enzymes compared to control rats.
Explanation of the increment of serum AST and ALT which are employed in the diagnosis of hepatic damage might be due to cytoplasmic location of these enzymes which are released into the circulation after cellular damage (Singh et al., 2001 ).
The increase in ALP level could be interpreted by Higgins, et al., (2001) and Tong et al., (2005) who stated that VPA is metabolized by fatty acid β-oxidation and conjugated by glucuronic acid with a minimal contribution by omega oxidation, chronic or high-dose VPA therapy inhibits β-oxidation. This causes a decrease in benign metabolites of β-oxidation and increases toxic metabolites of omega oxidation in compensation, which cause injury to bile duct epithelium.
Concerning the oxidative stress effects on hepatic tissues which appeared in the form of significant increase in MDA level, more evident in high dose VPA group, this was coincided with Siddiqui et al., (1999) and Tong et al., (2005) . These findings CV CV could be explained by Tabatabaei and Abbott, (1999) , who stated that VPA induced cytotoxicity through generalized formation of oxygen radicals against nuclear DNA. Also, Na et al., (2003) mentioned that cytotoxic activity of VPA is the result of generation of hydrogen peroxides and production of highly reactive hydroxyl radicals. Furthermore, it enhances the clearance of selenium, copper and zinc, subsequently leading to decreased synthesis of free radicals scavenging enzymes such as glutathione peroxidase and glutathione reductase activities. In addition, Pourahmad et al., (2012) reported that, cytotoxic action of VPA is mediated by lysosomal membrane leakiness along with reactive oxygen species (ROS) formation . Also, incubation of hepatocytes with VPA also caused rapid hepatocyte glutathione (GSH) depletion which is another marker of cellular oxidative stress.
Results of light microscope examination of stained liver sections of the present study had supported the above mentioned biochemical results where rats received VPA (200 mg/kg) showed patchy microvesicular steatosis, dilated congested central vein and sinusoids in some lobules. With increasing the dose of VPA (400 mg/kg), patchy microvesicular steatosis and focal necrosis of hepatocytes, in most of hepatic lobules were observed. VAP administration resulted in cells with weak cytoplasmic staining/localization of Bcl2 in the hepatocytes surrounding the central vein. It was weaker localized in group IIIb than IIIa.
Silymarin administration showed partial improvement. Hepatic plates return to normal in some areas as regarding marked regression in microvesicular steatosis in most of liver sections especially that received low dose VPA and partially regressed in high dose VPA. Bcl-2 localization revealed dark brown positive reaction in low dose VPA group and moderate brown positive reaction in high dose VPA group.
The histopathological findings of this study coincided with Baran et al., (2004) who mentioned that hepatic sections of rats treated with VPA showed congestion and dilatation of central veins, perivenullar sinusoids, increased vascularization, dilatation and microvesicular steatosis. In addition, degeneration and inflammation at the periportal zone were also detected.
These results were in accordance with Tong et al., (2005) ; Khan et al., (2005); and Lee, (2007) , who detected steatosis of zonal distribution conforming to the centrilobular zones, extensive necrosis, inflammatory cell infiltrations and dose / timedependent fatty changes around the central vein in liver sections of rats received VPA. In addition, Ibrahim, (2012) reported that VPA treated mice showed histopathological changes which included partial to severe distortion of liver architecture, congested vasculature, scattered to multifocal necrotic areas with focal aggregates of inflammatory cells, vacuolar degenerative changes, enlarged atypical hepatocytes, variation in nucleus regarding to size and shape and hypertrophied nucleus with fragmented chromatin.
The improvement that occurred after coadministration of silymarin with VPA could be explained by Vaziri and Rodriguez-Lturbe, (2006); Zarban and Ziaee, (2008) who stated that silymarin is a free radical scavenger and a membrane stabilizer which prevents lipid peroxidation and its associated cell damage in some experimental models. Silymarin can be very effective antioxidant and can protect biological systems against the oxidative stress.
Conclusion
The results of this study have shown that silymarin has protective effects against VPA induced hepatotoxicity, which might be due to the scavenging of free radicals. Therefore, we suggest that silymarin is potentially useful for the prevention of liver toxicity secondary to chronic administration of VPA.
Recommendation
− Silymarin recommended for patients on chronic or high-dose VPA therapy. − More studies with higher doses of silymarin are needed to evaluate its protective role on high doses of VPA therapy.
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